Trial Profile
Ozurdex in proliferative vitreoretinopathy; a randomised control trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Jun 2019
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary)
- Indications Proliferative vitreoretinopathy
- Focus Therapeutic Use
- 30 Mar 2016 Status changed from recruiting to completed.
- 30 Dec 2015 New trial record